Elevance Health (ELV) Stock Analysis: AI Score & Alternative Data
ELV alt-data: job postings climbing, web traffic lagging
Is Elevance Health a buy right now? The alternative data says hold. This ELV stock analysis is built on the 25+ alternative data signals AltIndex tracks on Elevance Health every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 48/100: a Hold. The stock trades at $419.09 with a $91B market cap.
The bullish side of the 90-day ledger: job postings up 26.5% to 382 open roles, and Reddit mentions up 100.0% to 2 a day. The drag: web traffic down 17.8% to 256K monthly visits, just 52% of employees report a positive business outlook, and sentiment down 50.0% to 50/100. That tension is what keeps the score mid-range.
ELV’s broader alt-data profile also covers headcount (44K employees, according to LinkedIn), quarterly revenue ($50.2B), and X followers (34K). Every signal links to its own page with full history, the ELV technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ELV is just below.
Elevance Health AI Stock Analysis
Elevance Health, a prominent player in the healthcare sector, focuses on providing a wide range of healthcare services. From insurance offerings to specialized health services, the company has a substantial presence in the market, facilitated by its robust infrastructure and strategic acquisitions.
Analysis generated June 30, 2026.
Recent Elevance Health Stock Alerts
|
Elevance Health | July 1 Price is up by 6.2% in the last 24h. |
|
Elevance Health | June 13 Insider Alert: Dixon Robert L JR is selling shares |
|
Elevance Health | June 4 Over the past few months, there has been a noticeable downward trend in Job postings. |
|
Elevance Health | June 1 Job postings are down by 30.5% in the last couple of days. |
Elevance Health Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 256K | 17.8% | |
| Job Posts | 382 | 26.5% | |
| LinkedIn Employees | 44K | 1.5% | |
| Employee Recommend | 57 | 3.4% | |
| Business Outlook | 52 | 1.9% | |
| Sentiment | 50 | 50.0% | |
| Reddit Mentions | 2 | 100.0% | |
| X Mentions | 5 | 75.0% | |
| Stocktwits Mentions | 3 | 90.0% | |
| News Mentions | 1 | 0% | |
| Stocktwits Subscribers | 5K | 1.1% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 34K | 0% | |
| Youtube Subscribers | 1K | 0.7% |
About Elevance Health (ELV)
Elevance Health, Inc. is an American health insurance provider. The company's services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans.
| Price | $419.09 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $91B |
| Year Range | $269 – $423 |
| Dividend Yield | 0% |
| PE Ratio | 17.6 |
| Analyst Rating | 38% buy |
| Industry | Insurance |
Latest Elevance Health News
View more → |
Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026July 6 - Morningstar.com |
Elevance Health (ELV) Enhances Health OS to Automate Clinical Reviews and Reduce Provider Administrative BurdensJuly 1 - Yahoo Entertainment |
|
Elevance Health (ELV) Fell Amid Healthcare Sector DownturnJune 29 - Yahoo Entertainment |
|
 |
Elevance Health's Q2 2026 Earnings: What to ExpectJune 26 - Biztoc.com |
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerJune 25 - GlobeNewswire |
|
Elevance Health Earnings & Financial Performance
View all earnings →Elevance Health Insider Trading Activity
View all →| Penczek Ronald W filed to sell 3,740 shares at $0.0. Jun 12 '26 |
| Dixon Robert L JR filed to sell 10,734 shares at $0.0. Jun 11 '26 |
| Penczek Ronald W filed to sell 4,109 shares at $0.0. May 19 '26 |
| SCHULMAN AMY W filed to sell 218 shares at $0.0. Mar 12 '26 |
| Kendrick Charles Morgan JR filed to sell 11,791 shares at $0.0. Mar 6 '26 |
Elevance Health Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lisa McClain |
Sep 15, 25 | Sell | $8K+ |
| Valerie Hoyle |
Sep 12, 25 | Buy | $8K+ |
| Gilbert Cisneros |
Sep 12, 25 | Buy | $8K+ |
| Lisa McClain |
Aug 13, 25 | Buy | $8K+ |
| Lisa McClain |
Aug 13, 25 | Buy | $8K+ |
Stocks Similar to Elevance Health
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
CignaCI |
$290.12 0.6% | $77B | 47 |
 |
AonAON |
$354.80 0.2% | $77B | 63 |
 |
Travelers CompaniesTRV |
$334.82 0.8% | $72B | 58 |
 |
ManulifeMFC |
$41.40 0.2% | $68B | 41 |
 |
Arthur J. Gallagher & Co.AJG |
$253.46 0.1% | $66B | 53 |
Explore Elevance Health Data
Frequently Asked Questions: Elevance Health (ELV)
Elevance Health has an AltIndex AI Score of 48/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
48/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Elevance Health (ELV) stock is $419.09 with a market cap of $91B.
As of today, Elevance Health’s PE (Price to Earnings) ratio is 17.6.
View the latest Elevance Health insider transactions to see recent buying and selling activity by company executives and directors.
Check the Elevance Health congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ELV stock price chart above shows Elevance Health’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Elevance Health technical analysis for RSI, moving averages, and more.
See the stocks similar to Elevance Health section on this page for companies in the same industry ranked by market cap and AI Score.
